Diese Analysten bewerten die MorphoSys-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 68,00 EUR | - | 06.05.2024 | |
| JP Morgan Chase & Co. | 31,00 EUR | - | 06.02.2024 | |
| Deutsche Bank AG | 25,00 EUR | - | 31.01.2024 | |
| Goldman Sachs Group Inc. | 17,50 EUR | - | 19.12.2023 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Agennix AG | 0 | 0 | 0 | - | - |
| Amgen Inc. | 0 | 0 | 0 | - | - |
| Bayer | 1 | 9 | 0 | 29,56 EUR | +47,32% |
| BB Biotech AG | 0 | 0 | 0 | - | - |
| Biogen Inc | 0 | 0 | 0 | - | - |
| Biotest AG | 0 | 0 | 0 | - | - |
| Eli Lilly | 1 | 0 | 0 | 994,00 USD | +37,36% |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | -0,10% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| MorphoSys | 1 | 3 | 0 | 35,38 EUR | - |
| Novartis AG | 3 | 5 | 1 | 99,62 CHF | +9,40% |
| Pfizer Inc. | 3 | 3 | 0 | 30,80 USD | +23,27% |
| QIAGEN N.V. | 6 | 2 | 0 | 47,97 EUR | +24,63% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 5 | 2 | 1 | 109,86 EUR | +21,07% |